A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Cogent Biosciences, Inc.
Cogent Biosciences, Inc.
Tango Therapeutics, Inc.
Astellas Pharma Inc
Tango Therapeutics, Inc.
Alentis Therapeutics AG
Elevar Therapeutics
Arvinas Inc.
Amgen
DualityBio Inc.
Bold Therapeutics, Inc.
Genfit
Apollo Therapeutics Ltd
Alaunos Therapeutics
TriSalus Life Sciences, Inc.
TCR2 Therapeutics
TCR2 Therapeutics
Medivir
TransThera Sciences (Nanjing), Inc.
Taiho Oncology, Inc.
BioNTech SE
NGM Biopharmaceuticals, Inc
TransThera Sciences (Nanjing), Inc.
NextCure, Inc.
Novo Nordisk A/S
Klus Pharma Inc.
Basilea Pharmaceutica
Beijing InnoCare Pharma Tech Co., Ltd.
Incyte Corporation
Genoscience Pharma
SMT bio Co., Ltd.
Senhwa Biosciences, Inc.
Celgene
Immunitor LLC
FeRx